07:46 AM EDT, 06/02/2025 (MT Newswires) -- Liquidia ( LQDA ) said Monday it is set to make its first commercial shipment of Yutrepia inhalation powder and the drug can now be prescribed via specialty pharmacies for pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease.

The company said a US court denied on May 30 United Therapeutics' ( UTHR ) request to block the launch of Yutrepia over alleged patent infringement.

The denial cleared the path for the full commercial launch of Yutrepia as United Therapeutics ( UTHR ) no longer has any motions pending against the drug, Liquidia ( LQDA ) said.

Yutrepia, or treprostinil, was approved by the US Food and Drug Administration on May 23 for the treatment of pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease.

Shares of Liquidia ( LQDA ) were up more than 9% in recent premarket activity Monday, while shares of United Therapeutics ( UTHR ) were down more than 1%.